IP Library Granted Patent US 8,399,210
Granted Patent B2
US 8,399,210 · App. 12/420,627 · Granted Mar 19, 2013

Autoantigenes for improved diagnosis, prognosis and treatment of inflammatory neurological diseases

Inventors: Ugur Sahin (Mainz, DE); Özlem Türeci (Mainz, DE); Alexander Zaigler (Hainburg, DE)
Assignees: Ganymed Pharmaceuticals AG; Johannes Gutenberg-Universitat
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,399,210
App. No.
12/420,627
Granted
Mar 19, 2013
Kind
B2
Abstract

According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful for diagnosis and treatment. A brain-specific expression of the autoantigens further emphasizes an important role of the antigens and antibodies in the origin and development of neurological autoimmune diseases.

Claims (11)

1. A method for the diagnosis of multiple sclerosis in a patient, comprising detection of moderately to strongly positive presence of autoantibodies, wherein the autoantibody is specific for a protein or peptide which is encoded by the nucleic acid sequence of SEQ ID NO: 1 in blood, serum or plasma isolated from a patient.

2. The method as claimed in claim 1 , where the protein or peptide for which the autoantibody is specific comprises the sequence of SEQ ID NO: 2.

3. The method as claimed in claim 1 or 2 , which further comprises detection of the autoantibody in blood, serum or plasma isolated from a patient without multiple sclerosis.

4. The method as claimed in claim 1 or 2 , where the detection of the autoantibody takes place with an immunoassay.

5. The method as claimed in claim 1 or 2 , where the detection of the autoantibody comprises

(i) contacting the blood, serum or plasma with an agent which specifically binds to the autoantibody, and

(ii) detecting the formation of a complex between the agent and the autoantibody.

6. The method as claimed in claim 5 , where the agent which specifically binds to the autoantibody is immobilized on a support material.

7. The method as claimed in claim 5 , where the agent which specifically binds to the autoantibody is a protein or peptide which specifically binds to the autoantibody.

8. The method as claimed in claim 7 , where the protein or peptide which specifically binds to the autoantibody comprises an amino acid sequence which is encoded by the nucleic acid of SEQ ID NO: 1.

9. The method as claimed in claim 7 , where the protein or peptide which specifically binds to the autoantibody comprises the sequence of SEQ ID NO: 2.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2010
From: SAHIN, UGUR; TURECI, OZLEM; ZAIGLER, ALEXANDER
To: GANYMED PHARMACEUTICALS AG, A GERMAN CORPORATION; JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Reel/Frame 024616/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2009
From: SAHIN, UGUR; TURECI, OZLEM; ZAIGLER, ALEXANDER
To: GANYMED PHARMACEUTICALS AG, A GERMAN CORPORATION; JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Reel/Frame 022869/0262 →
Priority Claims (1)
DE 10 2006 048 201 · Oct 11, 2006 · national
Continuity (2)
Continuation PCTEP2007008776 · Oct 9, 2007
Related Publication 20090252714A1 · Oct 8, 2009